Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000003223 | SCV000485475 | likely pathogenic | Metachromatic leukodystrophy | 2015-12-15 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000003223 | SCV000816680 | pathogenic | Metachromatic leukodystrophy | 2024-01-19 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 290 of the ARSA protein (p.Arg290Cys). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This missense change has been observed in individual(s) with clinical features of ARSA-related conditions (PMID: 7866401, 16678723, 17560502, 19815439, 26462614). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. This variant is also known as p.Arg288Cys. ClinVar contains an entry for this variant (Variation ID: 3077). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt ARSA protein function with a positive predictive value of 95%. This variant disrupts the p.Arg290 amino acid residue in ARSA. Other variant(s) that disrupt this residue have been observed in individuals with ARSA-related conditions (PMID: 10477432, 12809637, 16678723, 24001781, 26462614), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic. |
Molecular Medicine for Neurodegenerative and Neuromuscular Diseases Unit, |
RCV001642197 | SCV001519295 | pathogenic | Spastic ataxia | 2021-07-12 | criteria provided, single submitter | research | |
Fulgent Genetics, |
RCV000003223 | SCV002776151 | pathogenic | Metachromatic leukodystrophy | 2022-03-15 | criteria provided, single submitter | clinical testing | |
Gene |
RCV004819990 | SCV005440752 | pathogenic | not provided | 2024-06-26 | criteria provided, single submitter | clinical testing | Published functional studies found this variant is associated with significantly reduced enzyme activity (PMID: 37480112); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Also known as p.R288C; This variant is associated with the following publications: (PMID: 26462614, 7866401, 12809637, 24001781, 10477432, 34445196, 37480112, 19815439, 20339381, 16678723, 33855715, 17560502) |
OMIM | RCV000003223 | SCV000023381 | pathogenic | Metachromatic leukodystrophy | 2018-11-07 | no assertion criteria provided | literature only | |
Gelb Laboratory, |
RCV000003223 | SCV005046526 | not provided | Metachromatic leukodystrophy | no assertion provided | in vitro |